* Atrix Laboratories Inc., of Fort Collins, Colo., began Phase IIItrials of its subgingival drug delivery product to treat adultperiodontitis. The trials involve two studies at 20 sites and about 800patients.
* Cadus Pharmaceutical Corp., formerly of New York, has relocatedits research and administrative facilities to Tarrytown, N.Y.
* Gene Pharming Europe B.V., of Leiden, The Netherlands, hascross-licensed certain patents with Genzyme Transgenics Corp., ofFramingham, Mass., and acquired other patents from Biogen Inc., ofCambridge, Mass. All the patents are related to producing proteins inthe milk of transgenic animals. Gene Pharming is a subsidiary ofGenPharm International, of Mountain View, Calif., and GenzymeTransgenics is a subsidiary of Cambridge, Mass.-based GenzymeCorp.
* CytoTherapeutics Inc., of Providence, R.I., withdrew its proposedfollow-on public offering of 2 million shares, citing poor marketconditions and the company's cash reserves of about $19 million.CytoTherapeutics said it is pursuing alternate financing.
* Gensia Inc., of San Diego, received a product license in Sweden tomarket its GenESA system for diagnosing coronary artery disease inassociation with electrocardiography, echocardiography andradionuclide imaging.
* Martek Biosciences Corp., of Columbia, Md., said it plans to pay$10 million in cash, stock and promissory notes to purchase afermentation facility from Golden Technologies Co. Inc. inWinchester, Ky. The deal is expected to be finalized in March.
* Matritech Inc., of Cambridge, Mass., received a Small BusinessInnovative Research grant from the National Cancer Institute for$88,000. The funds will be used for cloning the gene that expressesPC-1, which has been identified as a prostate cancer-specific nuclearmatrix protein.
* SangStat Medical Corp., of Menlo Park, Calif., began volumemanufacturing of its Transtat product as part of a licensingagreement with Paris-based Diagnostica Stago S.A. Stago is usingTranstat in a diagnostic to test D-Dimer, which is associated withblood coagulation disorders. SangStat is developing Transtat forpost-transplant monitoring.
(c) 1997 American Health Consultants. All rights reserved.